- Home
- GAME vs SKYE Comparison
GAME vs SKYE Comparison
Compare GAME & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GAME | SKYE |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.4M | 44.9M |
| IPO Year | 2024 | 2013 |
Fundamental Metrics
Financial Performance| Metric | GAME | SKYE |
|---|---|---|
| Price | $0.32 | $0.76 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $14.75 |
| AVG Volume (30 Days) | ★ 1.1M | 259.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 37.72 | ★ 86.41 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,198,101.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.44 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 85.00 | N/A |
| 52 Week Low | $0.26 | $0.68 |
| 52 Week High | $2.87 | $5.75 |
Technical Indicators
Market Signals| Indicator | GAME | SKYE |
|---|---|---|
| Relative Strength Index (RSI) | 46.19 | 40.10 |
| Support Level | $0.27 | $0.68 |
| Resistance Level | $0.33 | $1.15 |
| Average True Range (ATR) | 0.03 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 56.59 | 43.87 |
Price Performance
Historical ComparisonAbout GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged in revolutionizing the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. It's next generation media, entertainment, and technology helps creators and maximize their brand partners' return on investment. Its purpose-built platform provides marketing and creative services, offers data and analytics solutions, and amplifies awareness through FaZe Clan.
About SKYE Skye Bioscience Inc.
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.